SAB Biotherapeutics (SABS) to Release Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABS) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect SAB Biotherapeutics to announce earnings of ($0.29) per share and revenue of $0.1250 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.15). On average, analysts expect SAB Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SAB Biotherapeutics Stock Up 6.2%

SABS stock opened at $3.79 on Tuesday. The company has a current ratio of 11.45, a quick ratio of 11.45 and a debt-to-equity ratio of 0.01. SAB Biotherapeutics has a 1 year low of $1.85 and a 1 year high of $5.15. The company has a fifty day simple moving average of $3.67 and a 200 day simple moving average of $3.83. The firm has a market cap of $289.78 million, a PE ratio of -1.80 and a beta of 0.53.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SABS. State of Wyoming acquired a new position in shares of SAB Biotherapeutics during the fourth quarter worth approximately $34,000. State Street Corp acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter worth $49,000. ADAR1 Capital Management LLC bought a new position in SAB Biotherapeutics during the third quarter worth $30,000. Dimensional Fund Advisors LP bought a new position in SAB Biotherapeutics during the third quarter worth $32,000. Finally, Persistent Asset Partners Ltd bought a new position in SAB Biotherapeutics during the fourth quarter worth $74,000. 7.82% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on SABS shares. Zacks Research raised shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Wednesday, July 8th. Chardan Capital upped their price target on SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Wall Street Zen lowered SAB Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday. Finally, Jefferies Financial Group started coverage on shares of SAB Biotherapeutics in a report on Wednesday, May 20th. They set a “buy” rating and a $11.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.